The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Clinical Trials, Phase I

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Clinical Trials, Phase I


Psychiatry related information on Clinical Trials, Phase I


High impact information on Clinical Trials, Phase I

  • CONCLUSION: We recommend comprehensive clinical toxicologic evaluation of combination therapy with O6-benzylguanine plus BCNU, which would allow subsequent design of phase I clinical trials [7].
  • SAHA is a potentially new therapeutic approach to cancer treatment and is in Phase I clinical trials [8].
  • The inhibitory activities of the NS1RM-Rev chimera were at least equivalent to those of the Rev M10 mutant protein, which has been considered to be the prototype trans inhibitor of Rev function and is currently in phase I clinical trials for the treatment of AIDS patients [9].
  • Adenoviral vectors and DNA-liposome complexes are being used to deliver the CF gene to patient airways in phase I clinical trials [10].
  • By screening a chemical library of >1000 compounds, 17-allyaminogeldanamycin (17AAG) was identified as a potent inhibitor of uPA by the National Cancer Institute and is now in Phase I clinical trials [11].

Chemical compound and disease context of Clinical Trials, Phase I


Biological context of Clinical Trials, Phase I


Anatomical context of Clinical Trials, Phase I


Associations of Clinical Trials, Phase I with chemical compounds


Gene context of Clinical Trials, Phase I


Analytical, diagnostic and therapeutic context of Clinical Trials, Phase I


  1. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Baldew, G.S., McVie, J.G., van der Valk, M.A., Los, G., de Goeij, J.J., Vermeulen, N.P. Cancer Res. (1990) [Pubmed]
  2. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Kirichenko, A.V., Rich, T.A., Newman, R.A., Travis, E.L. Cancer Res. (1997) [Pubmed]
  3. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Venner, P.M., Glazer, R.I., Blatt, J., Sallan, S., Rivera, G., Holcenberg, J.S., Lipton, J., Murphy, S.B., Poplack, D.G. Cancer Res. (1981) [Pubmed]
  4. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Hartman, N.R., Yarchoan, R., Pluda, J.M., Thomas, R.V., Wyvill, K.M., Flora, K.P., Broder, S., Johns, D.G. Clin. Pharmacol. Ther. (1991) [Pubmed]
  5. 3'-Deoxythymidin-2'-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. August, E.M., Birks, E.M., Prusoff, W.H. Mol. Pharmacol. (1991) [Pubmed]
  6. Vanoxerine National Institute on Drug Abuse. Preti, A. Current opinion in investigational drugs (London, England : 2000) (2000) [Pubmed]
  7. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., Schold, S.C. J. Natl. Cancer Inst. (1992) [Pubmed]
  8. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., Marks, P.A. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  9. New approach for inhibiting Rev function and HIV-1 production using the influenza virus NS1 protein. Qian, X.Y., Chen, Z.Y., Zhang, J., Rabson, A.B., Krug, R.M. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  10. Somatic gene therapy for cystic fibrosis. O'Neal, W.K., Beaudet, A.L. Hum. Mol. Genet. (1994) [Pubmed]
  11. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Nielsen, T.O., Andrews, H.N., Cheang, M., Kucab, J.E., Hsu, F.D., Ragaz, J., Gilks, C.B., Makretsov, N., Bajdik, C.D., Brookes, C., Neckers, L.M., Evdokimova, V., Huntsman, D.G., Dunn, S.E. Cancer Res. (2004) [Pubmed]
  12. A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose. Nagourney, R.A., Fox, P., Schein, P.S. Cancer Res. (1978) [Pubmed]
  13. Fostriecin: chemistry and biology. Lewy, D.S., Gauss, C.M., Soenen, D.R., Boger, D.L. Current medicinal chemistry. (2002) [Pubmed]
  14. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Hartman, N.R., Yarchoan, R., Pluda, J.M., Thomas, R.V., Marczyk, K.S., Broder, S., Johns, D.G. Clin. Pharmacol. Ther. (1990) [Pubmed]
  15. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Wang, Y.X., Freedberg, D.I., Yamazaki, T., Wingfield, P.T., Stahl, S.J., Kaufman, J.D., Kiso, Y., Torchia, D.A. Biochemistry (1996) [Pubmed]
  16. Recent developments in the field of tumor-inhibiting metal complexes. Galanski, M., Arion, V.B., Jakupec, M.A., Keppler, B.K. Curr. Pharm. Des. (2003) [Pubmed]
  17. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Burger, A.M., Hartung, G., Stehle, G., Sinn, H., Fiebig, H.H. Int. J. Cancer (2001) [Pubmed]
  18. Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Honore, S., Kamath, K., Braguer, D., Wilson, L., Briand, C., Jordan, M.A. Mol. Cancer Ther. (2003) [Pubmed]
  19. Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Honore, S., Kamath, K., Braguer, D., Horwitz, S.B., Wilson, L., Briand, C., Jordan, M.A. Cancer Res. (2004) [Pubmed]
  20. Sensitizers and protectors in radiotherapy. Brown, J.M. Cancer (1985) [Pubmed]
  21. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Baselga, J., Pfister, D., Cooper, M.R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, V., Waksal, H., Mendelsohn, J. J. Clin. Oncol. (2000) [Pubmed]
  22. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J.M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., Nicholson, R.I., Baselga, J. J. Clin. Oncol. (2002) [Pubmed]
  23. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Dorie, M.J., Brown, J.M. Cancer Res. (1993) [Pubmed]
  24. Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation. Ames, M.M., Richardson, R.L., Kovach, J.S., Moertel, C.G., O'Connell, M.J. Cancer Res. (1990) [Pubmed]
  25. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Hjarnaa, P.J., Jonsson, E., Latini, S., Dhar, S., Larsson, R., Bramm, E., Skov, T., Binderup, L. Cancer Res. (1999) [Pubmed]
  26. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Lotze, M.T., Custer, M.C., Sharrow, S.O., Rubin, L.A., Nelson, D.L., Rosenberg, S.A. Cancer Res. (1987) [Pubmed]
  27. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Sandor, V., Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M.V., Bates, S.E. Br. J. Cancer (2000) [Pubmed]
  28. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Juarez, J., Bendall, L., Bradstock, K. Curr. Pharm. Des. (2004) [Pubmed]
  29. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Reilly, J.T. Leuk. Lymphoma (2003) [Pubmed]
  30. Gene therapy of ovarian cancer. Bauknecht, T., Meinhold-Heerlein, I. Current women's health reports. (2002) [Pubmed]
  31. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Amit-Vazina, M., Shishodia, S., Harris, D., Van, Q., Wang, M., Weber, D., Alexanian, R., Talpaz, M., Aggarwal, B.B., Estrov, Z. Br. J. Cancer (2005) [Pubmed]
  32. Alterations in oxygen transport following WR-2721. Glover, D., Negendank, W., Delivoria-Papadopoulos, M., Glick, J.H. Int. J. Radiat. Oncol. Biol. Phys. (1984) [Pubmed]
  33. Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3. Candal, F.J., Bosse, D.C., Vogler, W.R., Ades, E.W. Cancer Chemother. Pharmacol. (1994) [Pubmed]
  34. Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9. Jonkman-de Vries, J.D., Talsma, H., Henrar, R.E., Kettenes-van den Bosch, J.J., Bult, A., Beijnen, J.H. Cancer Chemother. Pharmacol. (1994) [Pubmed]
  35. Clinical trial and pharmacokinetics of carboplatin 560 mg/m2 in children. Doz, F., Brugières, L., Bastian, G., Quintana, E., Lemerle, J., Zucker, J.M. Med. Pediatr. Oncol. (1990) [Pubmed]
WikiGenes - Universities